Baricitinib is safe and effective for treatment of refractory juvenile idiopathic arthritis

1. Time to disease flare was significantly shorter in the placebo group versus baricitinib. 2. There was no difference in serious adverse events between the baricitinib and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Juvenile idiopathic arthritis (JIA) is defined by the onset of polyarticular joint pain before age 16 and can severely

Related Keywords

,Rating Level ,Juvenile Arthritis Disease Activity Score ,Hospitalized Adults ,Between Dec ,Arthritis ,Enthesitis ,Enthesitis Related Arthritis ,Djia ,Joint Pain ,Juvenile Idiopathic Arthritis ,Juvenile Psoriatic Arthritis ,Pediatric Rheumatology ,Pediatrics ,Psoriatic Arthritis ,Rheumatology ,Systemic Jia ,Chronic Disease ,